Bracco molecular imaging subsidiary Blue Earth Diagnostics and Siemens Healthineers subsidiary PETNet Solutions have signed a new commercial supply contract for Blue Earth's Axumin (fluciclovine F-18) radiopharmaceutical and its investigational radiohybrid prostate-specific membrane antigen imaging agent, rhPSMA-7.3 (F-18).
Under the new multiyear deal, PETNet will expand production and continue distributing Axumin. It will also commercially manufacture and distribute rhPSMA-7.3 (F-18) pending its successful development and potential approval by the U.S. Food and Drug Administration (FDA), according to the companies. PETNet is already producing rhPSMA-7.3 (F-18) for Blue Earth's phase III clinical trials in patients with newly diagnosed or recurrent prostate cancer.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
